反应详情

The title compound was prepared in analogy to the procedure described for Example 25 but 2-bromo-5-(5-chloro-2-oxo-1,2-dihydro-pyridin-3-yl)-6-(4-chloro-phenyl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-b]pyrrol-4-one (Intermediate M) and 4-methoxy-N,N-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine (Intermediate W) were used instead of 2-bromo-5-(5-chloro-2-methyl-phenyl)-6-(4-chloro-phenyl)-1-isopropyl-5,6-dihydro-1H-pyrrolo[3,4-b]pyrrol-4-one and 4-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-pyrimidin-2-ylamine respectively to afford the title compound as a white solid. ESI-MS: tR=1.14 min, [M+H]+ 553/555 (LC-MS 1); 1H-NMR (d6-DMSO, 400 MHz): 12.15 (br s, 1H), 8.02 (s, 1H), 7.44 (s, 1H), 7.35-7.42 (m, 3H), 7.22 (m, 2H), 6.66 (s, 1H), 6.23 (s, 1H), 3.93 (m, 1H), 3.84 (s, 3H), 3.14 (s, 6H), 1.28 (m, 3H), 0.45 (m, 3H).

1. customThe title compound was prepared in analogy to the procedure